Dorman Products reports second-quarter results today against a backdrop of diverging signals: options traders have turned unusually bullish even as short sellers quietly add exposure and the stock slides toward the print.
The sharpest divergence is in the options market. Call demand is running well above normal — the put/call ratio has dropped to 0.625, more than two standard deviations below its 20-day average of 0.72. That is one of the lowest defensive readings of the past year, sitting near the 52-week floor of 0.40. The contrast with the price action is striking: DORM has fallen 4.1% in a single session and is off 6.4% on the week, closing at $127.68. Options traders appear to be fading the weakness rather than protecting against further downside.
Short interest tells a more cautious story from the positioning side. At 5.75% of the free float, shorts have added roughly 7.3% more exposure over the past week — a meaningful build in a relatively short window. That said, borrow conditions remain relaxed. The cost to borrow is just 0.52%, and availability is ample at 353%, meaning there is no shortage of shares for lenders and no squeeze pressure building in the lending market. The week-on-week availability tightening of about 7% is worth watching but does not yet signal a stressed borrow environment. The ORTEX short score of 55.9 is middling — elevated enough to note, but nowhere near extreme.
Analysts lean constructive but with caveats. Wells Fargo raised its target to $155 from $140 on July 21 while holding its Overweight rating, the most recent action and a sign of improving conviction from at least one bellwether-tier name. The broader consensus implies about 21% upside to a mean target of $154, though that gap has widened precisely because the stock has sold off. The bull case centers on Dorman's growth profile — forward EPS estimates are rising, with the 12-month forward EPS ranked in the 79th percentile year-on-year. Bears point to a valuation that, even after the recent pullback, prices in execution: the stock trades at roughly 14.9x trailing earnings and 10.5x EV/EBITDA, and the price-to-book ratio has compressed 23% over the past month as the stock has retreated. Historical earnings reactions offer limited comfort either way — the May print saw the stock fall 4.5% the following day, while a prior report delivered a 10.6% gain. The range of outcomes is wide.
The print will ultimately test whether Dorman's growth trajectory justifies the Street's $154 target at a moment when the stock is already trading 17% below that consensus — and whether the call-side optimism in the options market has the underlying earnings data to support it.
See the live data behind this article on ORTEX.
Open DORM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
